Viewing StudyNCT04442022



Ignite Creation Date: 2024-05-06 @ 2:51 PM
Last Modification Date: 2024-10-26 @ 1:38 PM
Study NCT ID: NCT04442022
Status: RECRUITING
Last Update Posted: 2024-06-05
First Post: 2020-06-10

Brief Title: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum R-GDP with or Without Selinexor in Patients with RelapsedRefractory Diffuse Large B-cell Lymphoma
Sponsor: Karyopharm Therapeutics Inc
Organization: Karyopharm Therapeutics Inc

Conditions & Keywords Data

Conditions:
Name
RelapsedRefractory Diffuse Large B-cell Lymphoma
Keywords:
Name View
R-GDP View
RelapsedRefractory DLBCL View
Rituximab-Gemcitabine-Dexamethasone-Platinum R-GDP View
Selinexor View
Karyopharm View
KCP-330 View
XPOVIO View
DLBCL View
XPORT-DLBCL-030 View